A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors

Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGFβ receptor involved in tumor angiogenesis.

(2017) L. W. Goff et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer

(2015) Fatima H. Karzai et al.   BJU INTERNATIONAL

Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study 0229N

(2015) Vicky Makker et al.   GYNECOLOGIC ONCOLOGY

A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib

(2015) AG Duffy et al.   United European Gastroenterology Journal

Molecular Pathways: Can Activin-like Kinase Pathway Inhibition Enhance the Limited Efficacy of VEGF Inhibitors?

(2014) R. S. Bhatt et al.   CLINICAL CANCER RESEARCH

An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer

(2014) M. S. Gordon et al.   CLINICAL CANCER RESEARCH

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial

(2014) A. Necchi et al.   INVESTIGATIONAL NEW DRUGS

Improved Survival Outcomes in Cancer Patients with Hereditary Hemorrhagic Telangiectasia

(2013) C. W. Duarte et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor-like Kinase-1 Ligand Trap, in Patients with Advanced Cancer

(2013) J. C. Bendell et al.   CLINICAL CANCER RESEARCH

Anti-human Activin Receptor-like Kinase 1 (ALK1) Antibody Attenuates Bone Morphogenetic Protein 9 (BMP9)-induced ALK1 Signaling and Interferes with Endothelial Cell Sprouting

(2012) Laurens A. van Meeteren et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model

(2012) Femke Heindryckx et al.   JOURNAL OF HEPATOLOGY

ALK1 as an emerging target for antiangiogenic therapy of cancer

(2011) S. I. Cunha et al.   BLOOD

Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies

(2011) Dana D. Hu-Lowe et al.   CANCER RESEARCH

Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis

(2010) Sara I. Cunha et al.   JOURNAL OF EXPERIMENTAL MEDICINE